Innovation Imperiled

US healthcare needs radical revision, but we can't wipe out innovation in the process.

Written byRichard Gallagher
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Healthcare spending in the United States is unsustainable. It topped $2.3 trillion in 2007—that's $7,600 for every man, woman and child. That wouldn't be quite so hard to swallow if the service was excellent, but it's spotty, especially for the 47 million uninsured. Reform is essential to reduce the financial burden and to make the system more accessible and equitable. The Office of Health Reform, led by Jeanne Lambrew, reporting to Health and Human Services Secretary Tom Daschle, is a welcome start.

But, while everyone would be delighted to return to 1970's healthcare costs, who among us wants to return to 1970's healthcare outcomes? Improvement in diagnostics, prevention, treatment, and professional training has been dramatic. Even though a radical overall is needed, we must support research and invention.

There's a chain of innovation in healthcare—it links basic science to start-up biotechs that develop promising leads to the multinational companies that ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies